Audience Unimpressed By Verve’s Base Playing

Verve’s shares dropped hard on its recent Phase I data, and it might be up to Lilly to retore investor confidence.    

Verve Therapeutics

Gene editing, with which Vertex Pharmaceuticals Incorporated has seen success, is one thing; base editing may be another. Shares in Verve Therapeutics, Inc. cratered on the NASDAQ after data presented at the American Heart Association on 12 November revealed that two patients treated with Verve’s base-editing anti-cholesterol therapy VERVE-101 suffered severe cardiovascular events.

Key Takeaways
  • Verve’s first base-editing therapy seems to work in patients with high cholesterol and heart disease

The company’s stock price fell 40% the day after the data were released, opening at $9.50 on 13 November, though...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By 

Series B cash will be used to advance its Stargardt disease gene therapy.

More from R&D

Pharma’s Space Trails Entering Transformative Era - Keytruda’s Been There

 

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By 

Series B cash will be used to advance its Stargardt disease gene therapy.

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

 

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.